| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3341835 | Autoimmunity Reviews | 2011 | 11 Pages |
ObjectivesTo analyze available evidence on vaccinations in paediatric patients with rheumatic and autoinflammatory diseases. This evidence formed the basis of the recently constructed European League against Rheumatism (EULAR) recommendations for vaccination of these patients.MethodsA systematic literature review in the MEDLINE and EMBASE databases was conducted using various terms for vaccinations, paediatric rheumatic and autoinflammatory diseases and immunosuppressive drugs. Only papers on paediatric patients (< 18 years of age) were selected. A panel of 13 experts in the field graded methodological quality and extracted data using predefined criteria.Results27 papers were available. No studies were found on autoinflammatory diseases. 14 studies considered live-attenuated vaccines. Evidence so far supports the safety and immunogenicity of non-live composite vaccines, although studies were underpowered to accurately assess safety. Live-attenuated vaccines did not cause disease flares or severe adverse events, not even in patients on methotrexate and low dose glucocorticosteroids. Seven patients on anti-TNFalpha therapy were described receiving the live-attenuated measles, mumps, rubella (n = 5) or varicella (n = 2) booster without severe adverse events.ConclusionsData on safety and efficacy of vaccinations in paediatric patients with rheumatic diseases is reassuring, but too limited to draw definite conclusions. More research is needed on the safety and efficacy of especially live-attenuated vaccines in patients with rheumatic and autoinflammatory diseases using high dose immunosuppressive drugs.
► This is a systematic literature review on vaccination in juvenile patients with rheumatic diseases. ► Non-live composite vaccines seem safe and immunogenic in these patients. ► Live-attenuated vaccines do not cause severe adverse events or disease flares and seem immunogenic. ► Studies are underpowered to evaluate rare severe adverse events or effects on disease. ► Data on live-attenuated vaccines and high dose steroids, DMARDs or biologics is scarce.
